The phase 3, CADENZA study (Part A, 26 weeks) demonstrated sutimlimab, but not placebo, led to improvements in mean Hb levels and markers of haemolysis, and clinically meaningful improvements in fatigue in patients with CAD and no recent history of transfusion.19 Here, GSTM1 is linked to cold agglutinin disease.